Aim The purpose of this study was in summary the characteristics, efficacy, and safety of vesicular monoamine transporter-2 (VMAT-2) inhibitors for treating tardive dyskinesia (TD). difference [SMD] =?0.40, 95% self-confidence period [CI] =?0.19, ?0.62, unavailable 134523-00-5 supplier for both evaluations), Goals scores improved a lot more with deutetrabenazine than placebo (place bo-subtracted treatment difference ?1.4,… Continue reading Aim The purpose of this study was in summary the characteristics,